News for Antisense Therapeutics Limited (ATHJF)

Published at

Dec 1, 2023 7:44 AM

by raskmedia.com.au

mixed

mixed

Choppy session to kick off the new month: Premier (ASX:PMV) rallies on AGM comments

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.20% to 7,073.20.

TRVC.DE PMV.AX CXOXF CXO.AX C.MX C.BA C PLS.AX MYR.AX MSB.AX BRG.AX ATHJF ANP.AX MXI.AX MQGPE.AX MQGPD.AX MQGPC.AX MQG.AX JAH IRE.AX GOR.AX DGH.AX

Read more →
Published at

Oct 20, 2023 6:48 PM

by globenewswire.com

mixed

mixed

Antisense Oligonucleotide (ASO) Therapeutics market is projected to grow at a CAGR of 14.5% by 2033: Visiongain

Visiongain has published a new report entitled Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033: Forecasts by Therapeutic Application...

KDNY IONS.MX IONS 0JDI.L ROGN.MX ROG.SW RO.SW RHHVF RHHBY RHHBF ICOTF ICO.V GERN DRNA ATHJF ANP.AX ALEC 0TDF.L 0QQ6.L 0IV3.L DUL.DE ARWR ALNY A1LN34.SA 0HI3.L 0HD2.L

Read more →
Published at

Dec 23, 2022 3:00 PM

by globenewswire.com

mixed

mixed

Antisense Oligonucleotide Therapeutics market is projected to grow at a CAGR of 13.71% by 2032: Visiongain Reports Ltd

Visiongain has published a new report entitled Antisense Oligonucleotide Therapeutics 2022-2032. It includes profiles of Antisense Oligonucleotide...

IONS.MX IONS GERN ATHJF ANP.AX 0JDI.L 0IV3.L DUL.DE ARWR ALNY A1LN34.SA 0HI3.L 0HD2.L

Read more →
Published at

Nov 11, 2022 5:21 AM

by stockhead.com.au

mixed

mixed

ScoPo’s Powerplays: Stress eases as ASX health stocks enjoy much needed rally

ASX health stocks are comfortably up this week after better than expected US inflation figures for October have boosted markets.

NAN.AX MVF.AX AVH.AX ANN.AX IPD.AX ATHJF ANP.AX

Read more →
Published at

Oct 27, 2022 5:00 PM

by globenewswire.com

mixed

mixed

Antisense Oligonucleotide Therapeutics market is projected to grow at a CAGR of 13.71% by 2032: Visiongain Reports Ltd

Visiongain has published a new report entitled Antisense Oligonucleotide Therapeutics 2022-2032. It includes profiles of Antisense Oligonucleotide...

IONS.MX IONS GERN ATHJF ANP.AX 0JDI.L 0IV3.L DUL.DE ARWR ALNY A1LN34.SA 0HI3.L 0HD2.L

Read more →
Published at

Oct 4, 2022 10:29 AM

by etfdailynews.com

positive

positive

Antisense Therapeutics Limited (ASX:ANP) Insider Ben Price Acquires 493,896 Shares

Read Antisense Therapeutics Limited (ASX:ANP) Insider Ben Price Acquires 493,896 Shares at ETF Daily News

ATHJF ANP.AX

Read more →
Published at

Aug 22, 2022 1:40 PM

by globenewswire.com

mixed

mixed

Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets

World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers...

SLGC NWE NRC IONS.MX IONS DCYHY DCYHF ATHJF ASXFY ASXFF ANP.AX 0JDI.L VGID

Read more →
Published at

Jun 22, 2022 3:15 PM

by globenewswire.com

positive

positive

New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2

LGMDR2, also referred to as dysferlinopathy, is a rare genetic muscle disease caused by mutations in the dysferlin gene (DYSF)Animal study conducted at...

ATHJF ANP.AX

Read more →
Published at

May 3, 2022 7:10 PM

by etfdailynews.com

positive

positive

Mark Diamond Acquires 244,687 Shares of Antisense Therapeutics Limited (ASX:ANP) Stock

Read Mark Diamond Acquires 244,687 Shares of Antisense Therapeutics Limited (ASX:ANP) Stock at ETF Daily News

ATHJF ANP.AX

Read more →
Published at

Mar 9, 2022 9:01 PM

by globenewswire.com

mixed

mixed

Antisense Therapeutics to present poster at world’s largest NMD conference

New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation...

IONS.MX IONS ATHJF ANP.AX 0JDI.L VGID DCYHY DCYHF ASXFY ASXFF

Read more →